What is ImmunityBio, Inc.'s Shariah compliance score?

ImmunityBio, Inc. (IBRX) has a Shariah compliance score of 79/100 (Grade: B+, Good). AAOIFI Standard No. 21 requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30%, (3) interest-bearing deposits below 30%, and (4) prohibited income below 5%.

Does ImmunityBio, Inc. pass AAOIFI screening?

ImmunityBio, Inc. (IBRX) passes AAOIFI Shariah screening. AAOIFI Standard No. 21 requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30%, (3) interest-bearing deposits below 30%, and (4) prohibited income below 5%. IBRX's debt-to-market-cap is 7.7%.

How much purification is needed for ImmunityBio, Inc.?

Muslim investors purify the portion of dividends and realized gains that comes from non-permissible income by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification computes the percentage and amount for ImmunityBio, Inc. (IBRX) using the latest financial data.

Where can I screen ImmunityBio, Inc. for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for ImmunityBio, Inc. (IBRX) and 8,200+ securities. US-listed stocks and ETFs are screened under AAOIFI Standard No. 21. Bursa Malaysia securities carry the Securities Commission Malaysia's official status. Coins are screened separately, under published scholarly opinion. The verdict is free, with no credit card or signup required for basic screening. The compliance grade, score, and debt ratio are free too; the full ratio breakdown is part of Pro.

IBRXHalalB+

Unlock full report, free

Compliance Status

Halal

Screened on Oct 15, 2026 · AAOIFI Standard 21

B+

Good

79Score

Is ImmunityBio, Inc. (IBRX) halal? Halal. Based on AAOIFI screening, ImmunityBio, Inc. passes both qualitative (business activity) and quantitative (financial ratio) screens with a compliance score of 79/100 (Grade: B+).

Quote this verdict

HalalScreener rates ImmunityBio, Inc. (IBRX) Halal, 79/100, grade B+ under AAOIFI Standard 21, screened Oct 15, 2026. Source: https://halalscreener.app/en/stock/IBRX

AvoidBorderlineClean

Business activity

What the company sells is permissible.

Passed

Company debt

Well clear of the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

7.7% of 30.0% limit

PRO DETAIL

The verdict above is final and free.

Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.

Card needed, nothing charged today

Screened according to AAOIFI Standard 21

What this means for you

You can own IBRX

It passes both the business activity and financial ratio screens under AAOIFI Standard 21.

Purification amount is Pro

We have screened IBRX's prohibited income, but the exact share you would need to purify is part of Pro.

Card needed, nothing charged today

IBRX: Is ImmunityBio, Inc. Halal?

ImmunityBio, Inc.

NASDAQHealthcareUS

$9.18

Market Cap: 9.7B

Get an email if IBRX's halal status changes

We re-screen ImmunityBio, Inc. daily. If the verdict moves, you hear about it the same day.

Free. One click sets it up, and you can unsubscribe any time.

About ImmunityBio, Inc.

ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.

Sector: Healthcare · Industry: Biotechnology

Shariah Compliance Status

AAOIFI Standard 21Updated Oct 15, 2026

Want to check the math yourself?

The verdict above is final and free. Pro members can verify every ratio behind it: interest-bearing deposits, prohibited income breakdown, and the full math.

Free for 7 days. Cancel anytime.

Card needed, nothing charged today

AI Compliance Insight

PRO

Institutional-grade Shariah analysis

Card needed, nothing charged today

See why IBRX is rated Halal with institutional-grade analysis

PRO DETAIL

The verdict above is final and free.

Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.

Card needed, nothing charged today

Screened according to AAOIFI Standard 21

Compliance History

Halalnow
since Oct 2026
Not Halal
until the change above
Halal
until the change above
Not Halal
until the change above
Halal
until the change above
Not Halal
until the change above

Tracked since Jun 2026. Updates automatically on each re-screen.

Fiscal: Q2 2026Data source: EDGAR

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

Free · No credit card required

Know the day IBRX's verdict changes

A free account keeps watch on 3 stocks and emails you when a verdict moves. You also get 3 questions for the AI Scholar. No card needed.

Get Started Free Browse Screener

8,200+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is ImmunityBio, Inc. (IBRX) halal to invest in?

Based on AAOIFI Standard 21 screening, ImmunityBio, Inc. (IBRX) is rated Halal with a compliance grade of B+ (Good). It passes both the business activity screen (no primary involvement in prohibited sectors) and the quantitative financial ratio screen (debt, interest deposits, and prohibited income all below AAOIFI thresholds).

Why did ImmunityBio, Inc. get a B+ compliance rating?

ImmunityBio, Inc. (IBRX) received a grade of B+ (Good) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 7.7% (limit 30%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change ImmunityBio, Inc.'s Shariah verdict?

ImmunityBio, Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is ImmunityBio, Inc. re-screened for Shariah compliance?

ImmunityBio, Inc. (IBRX) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Oct 15, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.